Information  X 
Enter a valid email address

Marshall Edwards (MSH)

  Print      Mail a friend

Tuesday 29 November, 2005

Marshall Edwards

MEI/Sanofi-Aventis Yale trial

Marshall Edwards, Inc.
28 November 2005

FOR IMMEDIATE RELEASE                               CONTACT: David Sheon
                                                             (202) 518-6321
                                                             [email protected]

New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian
Cancer Commences at Yale University School of Medicine

Combination therapy study to address major need in jumping hurdle of resistance
to standard treatments

(WASHINGTON/SYDNEY- November 28th, 2005) -- Marshall Edwards, Inc. announced
today plans for a Phase Ib/IIa clinical study of the investigational anti-cancer
drug, phenoxodiol in combination with docetaxel for women with recurrent ovarian
cancer. The investigator-initiated clinical study will take place at the Yale
University School of Medicine and is supported jointly by Sanofi-Aventis and
Marshall Edwards, Inc.

Docetaxel is a second-generation taxane that is commonly used in patients with
recurrent or persistent ovarian cancer that have failed other therapies,
including the first-generation taxane, paclitaxel.  In this setting, docetaxel
faces the challenge of a high level of drug resistance that has developed
following earlier therapy with paclitaxel and other agents. Under these
circumstances, the clinical response rate to any chemotherapeutic is often
limited due to the rapid development of chemo-resistance.  The purpose of the
study is to determine if the addition of phenoxodiol to docetaxel can improve
clinical response and survival by delaying or preventing the development of
chemo-resistance in women with recurrent ovarian cancer.

The study will enroll 60 women with recurrent epithelial ovarian, fallopian tube
or abdominal cavity cancer after treatment with a platinum and paclitaxel.  All
60 patients will be given docetaxel by injection weekly; half the patients will
also be given oral phenoxodiol daily, and the other half a placebo tablet. Tumor
response will be determined on the basis of tumor burden (RECIST criteria) in
patients with measurable disease, and tumor marker levels (GCIG criteria) in
patients with non-measurable disease.  Disease free survival, the time from
study enrollment to evidence of disease progression, will also be compared
between the two groups.  Treatment will continue for one year unless there is
evidence of unacceptable toxicity or disease progression.

The rationale behind this study is based on two observations. The first is the
demonstration in pre-clinical studies of the potent ability of phenoxodiol to
reverse chemo-resistance in human ovarian cancer cells to docetaxel, through the
ablation of anti-apoptotic proteins in the tumor cells.(1,2) The second is the
encouragingly high tumor response rate observed in a current clinical study
where phenoxodiol is being used to chemo-sensitize paclitaxel in advanced-stage
ovarian cancer patients where the tumor is taxane-resistant or refractory.

                                 -- M O R E --

Page 2-2-2-2

'Advanced-stage ovarian cancer is one of the most devastating forms of cancer,
with half of the women diagnosed with it dying within five years,' said Dr.
Thomas Rutherford, the study's Principal Investigator. 'One of the imperatives
facing doctors who treat these patients is to find ways to restore sensitivity
to drugs such as taxanes once they start to lose that sensitivity.'

'The highly encouraging pre-clinical and clinical data that we have seen with
phenoxodiol when it has been used as a chemo-sensitizer to date, gives us
optimism that this strategy will provide the means to improve the survival of
these late-stage cancer patients.'

The study is expected to open for enrollment immediately and calls should be
directed to 203-785-6956.

About Docetaxel

Docetaxel (Taxotere(R), Sanofi-Aventis) belongs to the taxane family of
anti-cancer agents that is characterized by their ability to inhibit cell
division by essentially 'freezing' the cell's internal skeleton which is
comprised of microtubules. Microtubules assemble and disassemble during cell
growth. Docetaxel blocks their disassembly, thereby preventing the cell from
dividing and leading ultimately to its death.

Docetaxel is approved by the FDA (i) for the treatment of women with early stage
breast cancer, locally advanced or metastatic breast cancer after failure of
prior platinum-based chemotherapy, (ii) for locally advanced or metastatic
breast cancer after anthracycline-based therapy,  (iii) as a first-line therapy
for non-small cell lung cancer, (iv) as a second-line therapy for non-small cell
lung cancer following prior treatment with cisplatin, and (v) for
hormone-refractory prostate cancer in combination with prednisone.

About Phenoxodiol

Phenoxodiol is an investigational drug and, as such, is not marketed in the
United States.

Phenoxodiol was granted fast-track status by the FDA in November 2004 for its
intended use in women with ovarian cancer.

Phenoxodiol is a novel acting drug that inhibits key pro-survival signalling
pathways generated by the sphingomyelin pathway. These pathways (eg.
sphingosine-1-phosphate) are over-active in tumor cells, and their inhibition by
phenoxodiol leads to the prevention of production of key pro-survival proteins
such as XIAP. XIAP, an anti-apoptotic protein, prevents cell death by blocking
signals coming from the death receptors on the cell surface. Removal of such
anti-apoptotic proteins restores the ability of tumor cells to undergo apoptosis
in response to chemotherapy.

The putative primary molecular target of phenoxodiol is a family of proteins
expressed on the surface of tumor cells, but not on non-tumor cells. The
restriction of expression of that family of proteins to tumor cells is thought
to account for the high specificity of phenoxodiol.

                                 -- M O R E --

Page 3-3-3-3
Phenoxodiol is able to kill ovarian cancer cells that are highly resistant to
standard anti-cancer drugs, as well as being able to restore sensitivity in
these cells to standard anti-cancer drugs such as taxanes.  These findings have
been borne out in recent clinical results showing that some women who have
stopped responding to taxane and platinum drugs had disease regression when
phenoxodiol was given in combination with their chemotherapy.(3)

About Ovarian Cancer

Ovarian cancer is the most lethal gynecological malignancy, and the fifth
leading cause of cancer related death in women in the United States.  The
American Cancer Society reports that an estimated 25,400 new cases of ovarian
cancer will be diagnosed each year in the United States and 14,300 deaths will
occur. One in 70 women will develop ovarian cancer and one out of 100 women will
die from this disease.  This high mortality is due mainly to the inability to
detect early disease, with approximately 80% of patients being diagnosed in
advanced-staged disease.  However, even in those patients diagnosed with Stage I
or Stage II disease, the five-year survival rate ranges from 60 to 90 percent
depending on the degree of tumor differentiation, and despite treatment advances
over the past decade, there has been no advance in overall survival. The reason
for this is the high rate of relapse.

Of patients who respond to first-line chemotherapy, less than 10 to 15 percent
of these will remain in remission, and most relapsed cases are chemo-resistant.
The failure of some ovarian cancers to respond to first-line chemotherapy and
the development of resistance to multi-drug therapies represent the major
hurdles to effective therapy of ovarian cancer.

About Sanofi-Aventis

The Sanofi-Aventis Group is the world's third largest pharmaceutical company,
ranking number one in Europe. Backed by a world-class R&D organization,
Sanofi-Aventis is developing leading positions in seven major therapeutic areas:
cardiovascular, thrombosis, oncology, metabolic diseases, central nervous
system, internal medicine, and vaccines. The Sanofi-Aventis Group is listed in
Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Marshall Edwards, Inc.

Marshall Edwards, Inc. (Nasdaq : MSHL) has licensed rights to bring phenoxodiol
to market globally from Novogen Limited (Nasdaq : NVGN). Marshall Edwards, Inc.
is majority owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on regulation of the
sphingomyelin pathway. Novogen, based in Sydney, Australia, is developing a
range of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases.

More information on phenoxodiol and on the Novogen group of companies can be
found at and

Under U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials. After the results of these trials are submitted in a new drug
application to the FDA, the FDA must approve the drug as safe and effective
before marketing can take place. Statements herein that are not descriptions of
historical facts are forward-looking and subject to risk and uncertainties.
Actual results could differ materially from those currently anticipated due to a
number of factors, including those set forth in the Company's Securities and
Exchange Commission filings under 'Risk Factors,' including risks relating to
the early stage of products under development; uncertainties relating to
clinical trials; dependence on third parties; future capital needs; and risks
relating to the commercialization, if any, of the Company's proposed products
(such as marketing, safety, regulatory, patent, product liability, supply,
competition and other risks).


1..            Kamsteeg M et al., 2003.  Phenoxodiol - an isoflavone analog -
induces apoptosis in chemoresistant ovarian cancer cells.  Oncogene 22:2611.

2.             Sapi E., et al, 2004.  Resistance of Ovarian Cancer Cells to
Taxotere (Docetaxel) is XIAP Dependent and Reversible by Phenoxodiol.  Oncology 
Research, 14, 567-578.

3.             Rutherford, T., et al.  2004.  Phenoxodiol Phase Ib/II Study in
Patients with Recurrent Ovarian Cancer that are Resistant to Second Line 
Chemotherapy. AACR 95th Annual Meeting Orlando FL Abstract #4457.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                                                                                           

a d v e r t i s e m e n t